BlackRock (BLK) (SGEN) (TRGT) (XRTX) (APOL) (DECK) Ratings Reiterated

BlackRock, Inc. (NYSE: BLK), Seattle Genetics, Inc. (NASDAQ: SGEN), Targacept Inc. (NASDAQ: TRGT), Xyratex Ltd. (NASDAQ: XRTX), Apollo Group, Inc. (NASDAQ: APOL) and Deckers Outdoor (NASDAQ: DECK) had ratings on them reiterated by analysts.

Seattle Genetics, Inc. (SGEN) had its “Buy” rating reiterated by Needham & Company.

Targacept Inc. (TRGT) had its “Hold” rating reiterated by Needham & Company.

Xyratex Ltd. (XRTX) had its “Buy” rating reiterated by Needham & Company.

Apollo Group, Inc. (APOL) had its “Buy” rating reiterated by Deutsche Bank (NYSE:DB).

BlackRock, Inc. (BLK) had its “Hold” rating reiterated by Jefferies Group (NYSE:JEF).

Deckers Outdoor (DECK) had its “Buy” rating reiterated by Canaccord Genuity.

Targacept (TRGT) (IPAR) (CCUR) (FES) (RLOC) (STLY) Biggest NASDAQ Losers

Targacept Inc. (NASDAQ:TRGT), Inter Parfums Inc. (NASDAQ:IPAR), Concurrent Computer (NASDAQ:CCUR), Forbes Energy Services Ltd (NASDAQ:FES), ReachLocal Inc. (NASDAQ:RLOC) and Stanley Furniture Co. (NASDAQ:STLY) were the biggest losers on the NASDAQ.

Targacept Inc. (TRGT) ended the session down 35.09 percent, closing at $5.05. They traded in a range of $4.92 to $6.00. A total of 6,672,004 shares changed hands.

Inter Parfums Inc. (IPAR) ended the session down 7.98 percent, closing at $16.27. They traded in a range of $15.86 to $18.21. A total of 310,900 shares of the stock were traded.

Concurrent Computer (CCUR) ended the session down 6.14 percent, closing at $3.21. They traded in a range of $3.21 to $3.41. A total of 26,290 shares of the stock were traded.

Forbes Energy Services Ltd (FES) ended the session down 5.66 percent, closing at $5.50. They traded in a range of $5.40 to $5.99. A total of 70,149 shares of the stock were traded.

ReachLocal Inc. (RLOC) ended the session down 5.27 percent, closing at $6.65. They traded in a range of $6.50 to $7.18. A total of 503,742 shares of the stock were traded.

Stanley Furniture Co. (STLY) ended the session down 5.23 percent, closing at $3.08. They traded in a range of $3.00 to $3.11. A total of 111,136 shares of the stock were traded.

Ratings on (SFY) (SLAB) (TCAP) (TRGT) Upgraded

Ratings on Swift Energy (NYSE: SFY), Silicon Laboratories (NASDAQ: SLAB), Triangle Capital Corp. (NASDAQ: TCAP) and Targacept Inc. (NASDAQ: TRGT) upgraded by analysts today.

Jefferies (NYSE:JEF) upgraded shares of Swift Energy (SFY) from a “hold” rating to a “buy” rating. They have a price target of $46.00 on the company, up from $44.00.

JMP Securities upgraded Silicon Laboratories (SLAB) from a “market perform” rating to an “outperform” rating. They have a price target of $52.00 on the company.

Robert W. Baird upgraded Triangle Capital Cor (TCAP) from a “neutral” rating to an “outperform” rating. They have a price target of $21.00 on the company, up from $20.00.

Needham & Company upgraded Targacept Inc. (TRGT) from a “buy” rating to a “strong buy” rating. They have a price target of $32.00 on the company.

Targacept (NASDAQ:TRGT) Valuation Low Based on TC-5214 Program Says Needham

The valuation of Targacept (NASDAQ:TRGT) appears to be low, according to Needham, citing the strength of their TC-5214 program and the NNR pipeline.

Needham says, "All five planned Phase 3 TC-5214 trials in depression have been initiated by collaborator AstraZeneca (N/R), with initial topline results on track for YE11. We are favorably inclined based on impressive Phase 2 data announced in 2009. Valuation is low in our opinion (EV $500MM), given the strength of the TC-5214 program and the depth of the NNR pipeline in cognition and inflammatory disease. We reiterate our rating and price target. The stock was a favorite in 2010 and remains so into 2011."

Needham & Company reiterates a "Buy" rating on Targacept, which closed Thursday at $26.76, down $0.22, or 0.82 percent.

Targacept (NASDAQ:TRGT) Valuation Low Says Needham

Needham & Company said they believe the valuation of Targacept (NASDAQ:TRGT) is low based on TC5214 in depression and their work in the inflammation segment as well.

Needham said, "Management provided an overview and update of the company pipeline and platform yesterday at an investor meeting in NYC. We are incrementally more positive on TC5214 commercial positioning in the depression space and, although still early, we believe the company’s efforts in inflammation may prove to be an important value-driver in the long-term. Current valuation is low in our opinion (EV $360MM), given strength of the TC5214 program and depth of the NNR pipeline in cognition and inflammatory disease...We expect the stock to appreciate in 2011 as TC5214 results approach (YE11), with modest volatility in the interim tied to events from the cognition pipeline."

Targacept closed Friday at $21.92, down by $0.07, or 0.32 percent. Needham has a price target of $32 on them and maintains a "Buy" rating.

Targacept (NASDAQ:TRGT) Valuation Low Says Needham

Saying they believe the valuation on Targacept (NASDAQ:TRGT) is too low, Needham & Company maintains their "Buy" rating on the company.

"Targacept is scheduled to hold an investor R&D day tomorrow (Thursday) in NYC. Valuation is low in our opinion (EV $340MM), given the strength of the TC-5214 program in depression and the depth of the NNR pipeline in cognition and inflammatory disease...We continue to believe the depression market is attractive for add-on agents," said Needham.

Targacept closed Wednesday's trading session at $21.84, increasing by $0.64, or 3.02 percent. Needham as a price target on them of $32.